New combo therapy aims to stop cancer spread in patients with few metastases
NCT ID NCT07481799
First seen Mar 20, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This study tests whether adding a targeted drug (MRG003) to precise radiation therapy can help control cancer in people with EGFR-positive tumors that have spread to up to 5 spots. About 200 adults aged 18-75 with controlled primary tumors will receive the combination. The goal is to see if this approach delays cancer growth and extends survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGO-METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fifth Affiliated Hospital,Sun Yat-sen University
NOT_YET_RECRUITINGZhuhai, Guangdong, 519099, China
-
The Fifth Affiliated Hospital,Sun Yat-sen University
RECRUITINGZhuhai, Guangdong, 519099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.